Mylan CEO Heather Bresch delivered a defiant performance before a group of hostile lawmakers upset over the company’s EpiPen’s price hike, as she called the current $600 price tag “fair.”
Bresch refused to apologize before the House Oversight and Government Reform Committee Wednesday for raising the price by more than 400 percent since the generic drug maker acquired the allergy treatment in 2007. She said in her opening statement that Mylan regrets not anticipating the magnitude of a “growing minority of patients who may have ended up paying the full [wholesale acquisition cost] price and more.”
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.